To include your compound in the COVID-19 Resource Center, submit it here.

FDA panel backs Celebrex for juvenile RA

FDA's Arthritis Drugs Advisory Committee voted 15-1 that the risk/benefit ratio of Celebrex celecoxib

Read the full 140 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE